March 1, 2022

Fresenis Kabi AG
% Keith Dunn
Director Regulatory Affairs
Fresenius Kabi LLC, USA
3 Corporate Dr Suite 300
Lake Zurich, Illinois 60047

Re: K210073
Trade/Device Name: Agilia VP Infusion System, Agilia VP MC WIFI Infusion Pump, Volumat Lines Administration Sets, Agilia Link, Agilia Duo
Regulation Number: 21 CFR 880.5725
Regulation Name: Infusion Pump
Regulatory Class: Class II
Product Code: FRN, MRZ, FPA
Dated: January 8, 2021
Received: January 12, 2021

Dear Keith Dunn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Courtney H. Lias, Ph.D.
Director
OHT3: Office of GastroRenal, ObGyn,
General Hospital and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2023
See PRA Statement below.

510(k) Number *(if known)*
K210073

Device Name
Agilia VP Infusion System

Indications for Use *(Describe)*
The Agilia VP Infusion System is intended for adult and pediatric care for the intermittent or continuous delivery of parenteral fluids, medications, blood and blood derivatives through clinically accepted parenteral routes of administration. These routes of administration include intravenous, intra-arterial, subcutaneous and intraosseous using dedicated administration sets.

The Agilia VP Infusion System is also intended for neonatal care for the intermittent or continuous delivery of parenteral fluids for hydration and nutrition, blood and blood derivatives through clinically accepted parenteral routes of administration. These routes of administration include intravenous, intra-arterial, and subcutaneous using dedicated administration sets.

It is intended for use by trained healthcare professionals in healthcare facilities.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) SUMMARY

Date Prepared

February 28, 2022

Owner/Operator

Fresenius Kabi AG
61346 Bad Homburg
Germany

Owner/Operator Number: 9027285

Contact Person

Keith Dunn
Director, Regulatory Affairs
Fresenius Kabi USA, LLC
Three Corporate Drive, 2nd Floor
Lake Zurich, IL 60047 USA

Phone: 224-817-2430
Fax: 847 550 2960
E-mail: keith.dunn@fresenius-kabi.com

Secondary Contact Person

Jason Ma
Sr. Manager, Regulatory Affairs
Fresenius Kabi USA, LLC
Three Corporate Drive, 2nd Floor
Lake Zurich, IL 60047 USA

Phone: 224-817-4100
Fax: 847 550 2960
E-mail: Jason.ma01@fresenius-kabi.com

Device Trade Name

Agilia VP Infusion System

Common Name/Usual Name:

Infusion Pump and Accessories

Classification Name

21 CR 880.5725 Infusion Pump

Product Code and Classification Panel

The Agilia VP Infusion System (pump, set and accessories) has been classified as Class II under 21 CFR 880.5725, and reviewed by the General Hospital Devices Panel (80). For reference, the product code and classification of each device subsystem is identified in Table 1.

Table 1: Device Classification

Device Name	Regulation Number	Class	Description	Panel	Product Code
Agilia VP MC WiFi Volumetric Infusion Pump	21 CFR 880.5725	II	Infusion Pump	80	FRN
Agilia Link	21 CFR 880.5725	II	Infusion pump accessories	80	MRZ
Agilia Duo	21 CFR 880.5725	II	Infusion pump accessories	80	MRZ
Agilia USB Cable	21 CFR 880.5725	II	Infusion pump accessories	80	MRZ
Volumat Line administration sets	21 CFR 880.5725	II	Infusion pump accessories	80	FPA

Legally Marketed Device Under Which Substantial Equivalence is Being Claimed

Agilia Infusion System (K121613)

Device Description

The Agilia VP Infusion System includes the Agilia VP MC WiFi Volumetric Infusion Pump, which is a programmable electronic medical system dedicated to administering a pre-determined volume of an infusion product at a programmed rate, in combination with Volumat Line administration sets and optional accessories. The optional accessories are identified as follows:

- Agilia Link 4, 6 and 8 – Stacking rack system intended to power and organize 4, 6 or 8 pumps at the patient bedside.
- Agilia Duo – two-channel accessory designed to power two Agilia infusion pumps.
- Agilia USB Cable - intended to connect the Agilia VP infusion pump to a PC for serial communication.

Statement of Intended Use/Indications For Use

The Agilia VP Infusion System is intended for adult and pediatric care for the intermittent or continuous delivery of parenteral fluids, medications, blood and blood derivatives through clinically accepted parenteral routes of administration. These routes

of administration include intravenous, intra-arterial, subcutaneous and intraosseous using dedicated administration sets.

The Agilia VP Infusion System is also intended for neonatal care for the intermittent or continuous delivery of parenteral fluids for hydration and nutrition, blood and blood derivatives through clinically accepted parenteral routes of administration. These routes of administration include intravenous, intra-arterial, and subcutaneous using dedicated administration sets.

It is intended for use by trained healthcare professionals in healthcare facilities.

Technological Comparison as Compared to the Predicate Device

A comparison between the predicate device and the subject device is provided in the Table 2.

Table 2: Predicate Comparison

Characteristic	Predicate Device K121613	Subject Device K210073	Comment
Intended Use / Indications for Use	The Agilia Infusion System is a transportable equipment intended for use by trained healthcare professionals in healthcare facilities and homecare environments on adults, pediatrics and neonate's human patients to administer via a single channel or mounted on a multiple channels rack accessory: • Intermittent or continuous delivery of parenteral fluids (solutions, colloids, parenteral nutrition) and medications (including but not limited to diluted drugs, chemotherapy) through clinically accepted IV routes of administration. • Transfusion of blood and blood derivatives products.	The Agilia VP Infusion System is intended for adult and pediatric care for the intermittent or continuous delivery of parenteral fluids, medications, blood and blood derivatives through clinically accepted parenteral routes of administration. These routes of administration include intravenous, intra-arterial, subcutaneous and intraosseous using dedicated administration sets. The Agilia VP Infusion System is also intended for neonatal care for the intermittent or continuous delivery of parenteral fluids for hydration and nutrition, blood and blood derivatives through clinically accepted parenteral routes of administration. These routes of administration include intravenous, intra-arterial, and subcutaneous using dedicated administration sets. It is intended for use by trained healthcare professionals in healthcare facilities.	Similar The intended use between the predicate and proposed device are the same in terms of intended patient, route of administrations, and treatment. Per FDA guidance, the statement was revised to specifically name the intended routes of administration and to differentiate the intended patient population .
Type of Pump	Volumetric, Linear Peristaltic Pump	Volumetric, Linear Peristaltic Pump	Same
Patient Population	Adults, pediatrics, neonates	Adults, pediatrics, neonates	Same
Delivery Modes	Continuous, Intermittent, Primary, Secondary, KVO, Bolus (Manual and Programmable), Loading Dose	Continuous, Intermittent, Primary, Secondary, KVO, Bolus (Manual and Programmable), Loading Dose, Ramp-up / Ramp down, Sequential	Similar Performance testing demonstrates the additional modes do not introduce any new issues of safety or effectiveness.

Characteristic	Predicate Device K121613	Subject Device K210073	Comment
Infusion Accuracy	± 5%	± 5% under most conditions	Similar Detailed flow rate accuracy disclosed in the labeling
WIFI	No	Yes	Similar Performance testing demonstrates the addition of WIFI functionality does not introduce any new issues of safety or effectiveness.
Pump Control	Microcontroller controlled	Microcontroller controlled	Same
Number of Channels	1	1	Same
Mechanical Sensors	air, occlusion, temperature, pressure, door, set installation	air, occlusion, temperature, pressure, door, set installation	Same
Barcoding	No	No	Same
Automated Programming	No	No	Same
Manual Programming	Yes	Yes	Same
Piggy back / secondary	Yes	Yes	Same
Alarms	Air, occlusion, temperature, system malfunction, set installation, door, low drug reservoir volume, infusion complete, battery, technical	Air, occlusion, temperature, system malfunction, set installation, door, low drug reservoir volume, infusion complete, battery, technical	Same
Clinical Advisories	Yes	Yes	Same
Infusion Modes	Basic, continuous, intermittent, primary / secondary, KVO, Bolus (direct and programmed), Loading Dose	Basic, continuous, intermittent, primary / secondary, KVO, Bolus (direct and programmed), Loading Dose, Ramp-up / Ramp Down, Sequential	Similar Performance testing demonstrates the additional infusion modes do not introduce any new issues of safety or effectiveness.

Characteristic	Predicate Device K121613	Subject Device K210073	Comment
Features	Keypad lock	Keypad lock/automatic lock, occlusion auto restart	Similar Performance testing demonstrates the additional keypad features do not introduce any new issues of safety or effectiveness.
Dose Error Reduction Software / Drug Library Software Compatibility	Basic Profile (within pump)	Basic Profile (within pump)	Same
Wireless Server Software	No	Yes	Similar Performance testing demonstrates the addition of wireless server software does not introduce any new issues of safety or effectiveness.
Administration Sets	Volumat Line administration sets	Volumat Line administration sets	Same
Racking / Organization / Power	Link+ Agilia	Agilia Link	Similar Simpler, non-communicating accessory for proposed device
	Agilia Duo	Agilia Duo	Same
Electrical Safety	IEC 60601-1: 1998 +A1:1995 (2nd edition) IEC 60601-1-8: 2003 +A1:2006 IEC 60601-1-2: 2007 ANSI/AAMI ID26: 2004/(R)2009	IEC 60601-1: 2005 +A1:2012 (3rd edition) IEC 60601-1-8: 2012 IEC 60601-1-2: 2014 ANSI/AAMI ID26: 2004/(R)2009	Similar Performance testing demonstrates the application of state-of-the-art standards does not introduce any new issues of safety or effectiveness.
Mechanical / Power Specifications	Pump Size: 5.3 x 7.5 x 6.7 inches Pump Weight: App. 4.4 lbs. Line Power: 100-240 VAC	Pump Size: 5.3 x 7.5 x 6.7 inches Pump Weight: App. 4.4 lbs. Line Power: 100-240 VAC	Same
Operating Environment	Temperature: 41° F to 104° F Relative Humidity: 20-90% w/o condensation	Temperature: 41° F to 104° F Relative Humidity: 20-90% w/o condensation	Same

Characteristic	Predicate Device K121613	Subject Device K210073	Comment
Storage Environment	Temperature: 14° F to 140° F Relative Humidity: 10-90% w/o condensation	Temperature: 14° F to 140° F Relative Humidity: 10-90% w/o condensation	Same

To demonstrate substantial equivalence between the subject and predicate device the following non-clinical tests were performed:

- Verification testing of product requirements.
- Human factors engineering testing of product requirements associated with critical tasks.
- Testing for the reliability goals of the device.

Non-Clinical Testing

A safety assurance case was provided for the Agilia VP Infusion System as recommended in the FDA Guidance Document, Infusion Pumps Total Product Life Cycle issued December 2, 2014.

The stated goal of the safety assurance case is:

- The system design is acceptably safe for its intended use by its intended users and in its intended use environment.

The assurance case defines the device system, including the operational description, system definition, indications for use, patient population, intended users and use environments. The supporting assurance arguments covered the following attributes:

- Residual risks are analyzed and determined to be acceptably low using industry-standard risk analysis practices and regulatory guidance
- The Agilia VP Infusion System is at least as safe as an equivalent infusion system.
- The Agilia VP Infusion System is Verified and Validated for its intended use as it relates to safety
- The Agilia VP Infusion System is reliable over the system's expected lifetime.

The following evidence was included in the safety assurance case:

- Risk Management File

- Design verification and validation testing confirmed the Agilia VP Infusion System met user needs and design inputs. Testing results conformed with acceptance criteria. Flow rate and bolus accuracy testing were conducted by following AAMI TIR101 2021.

- Device reliability activities, testing and statistical analysis confirmed the Agilia VP Infusion System met its reliability goal at the system, device subsystem, and subsystem component level.

- Software verification and validation were performed per FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices issued May 11, 2005.

- Human factors evaluation conducted to validate the effectiveness of use-related features/functionality and use error-related mitigations in the associated use environments. IEC 62366-1 Edition 1.0 2015 Medical Devices Part 1: Application of usability engineering to medical devices was followed

- Electrical and Electromagnetic Compatibility testing were conducted. The Infusion System complies with the following standards:

    - Electrical Safety per IEC 60601-1

    - EMC testing per IEC 60601-1-2

- Cybersecurity testing performed confirmed the system is effective in addressing cybersecurity threats.

    - Content of Premarket Submissions for Management of Cybersecurity, October 2, 2014

    - Postmarket Management of Cybersecurity in Medical Devices, December 28, 2016

Clinical Testing

Clinical evaluation is not required for this submission to support substantial equivalence. Human Factors studies have been conducted on the subject device demonstrating passing results.

Conclusion

The results of software, electrical safety, system verification and validation testing conclude that the Agilia VP Infusion System is safe and effective for the intended users, uses and use environments, and that no further clinical investigation or testing is needed. The methods and results described in the verification and human factors evaluation (HFE/UE) reports support this conclusion.

Results of verification and validation activities demonstrate that the Agilia VP Infusion System is substantially equivalent to the predicate Agilia Infusion System (K121613).